Ismail A. Walbi

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz et al. · Clinical Cancer Research · 2016 · 65 citations · Full text

Medicine, Oncology, Pharmacology +14

Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization,<i>in vitro</i>and<i>in vivo</i>anti-prostate cancer activity, and mechanisms of action

Sukesh Voruganti, Jiang‐Jiang Qin, Sushanta Sarkar et al. · Oncotarget · 2015 · 63 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Roflumilast protects from cisplatin-induced testicular toxicity in male rats and enhances its cytotoxicity in prostate cancer cell line. Role of NF-κB-p65, cAMP/PKA and Nrf2/HO-1, NQO1 signaling

Basel A. Abdel‐Wahab, Ismail A. Walbi, Hassan A. Albarqi et al. · Food and Chemical Toxicology · 2021 · 51 citations

Medicine, Oncology, Pharmacology +14

Development of a Curcumin-Loaded Lecithin/Chitosan Nanoparticle Utilizing a Box-Behnken Design of Experiment: Formulation Design and Influence of Process Parameters

Ismail A. Walbi, Mohammad Zaki Ahmad, Javed Ahmad et al. · Polymers · 2022 · 42 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Nanoengineered chitosan functionalized titanium dioxide biohybrids for bacterial infections and cancer therapy

Mohammad Shabib Akhtar, Chandrasekaran Karthikeyan, Sharmila Saminathan et al. · Scientific Reports · 2024 · 42 citations · Full text

Natural Sciences, Chemistry, Materials Science +17